🇺🇸 FDA
Pipeline program

randomized, double-blinded, placebo-controlled

REC611-IIT-1

Phase 1 mab active

Quick answer

randomized, double-blinded, placebo-controlled for Prevention of COVID-19 Caused by SARS-CoV-2 is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Prevention of COVID-19 Caused by SARS-CoV-2
Phase
Phase 1
Modality
mab
Status
active

Clinical trials